Cambodia vs Eswatini: Average cost of multi drug-resistant tuberculosis treatment
Cambodia
850 constant 2022 US$
in 2024
Eswatini
840 constant 2022 US$
in 2024
Cambodia rank
58th
Eswatini rank
59th
Average cost of multi drug-resistant tuberculosis treatment over time
- Cambodia
- Eswatini
How they compare
Cambodia currently reports 850 constant 2022 US$ against 840 constant 2022 US$ in Eswatini, a difference of 10 constant 2022 US$.
The two have swapped places 1 time across 7 shared years of data; in 2017 it was Eswatini ahead.
Cambodia ranks 58th and Eswatini ranks 59th of 92 countries.
Eswatini has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Cambodia | Eswatini | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,247 constant 2022 US$ | 6,118 constant 2022 US$ | 3,871 constant 2022 US$ | Eswatini |
| 2020s | 1,688 constant 2022 US$ | 2,542 constant 2022 US$ | 855 constant 2022 US$ | Eswatini |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Cambodia or Eswatini?
- Cambodia, at 850 constant 2022 US$ against 840 constant 2022 US$ in Eswatini as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Cambodia and Eswatini?
- 10 constant 2022 US$, with Cambodia ahead.
- How many years of comparable data are there for Cambodia and Eswatini?
- 7 years are reported by both, from 2017 to 2024.
- How do Cambodia and Eswatini rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Cambodia ranks 58th and Eswatini ranks 59th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.